bioMerieux

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Type
Public
HQ
Marcy L'Étoile, FR
Founded
1963
Size (employees)
9,376 (est)
bioMerieux was founded in 1963 and is headquartered in Marcy-l'Étoile, FR

bioMerieux Office Locations

bioMerieux has an office in Marcy-l'Étoile
Marcy L'Étoile, FR (HQ)
376 Chemin De L'orme

bioMerieux Metrics

bioMerieux Financial Metrics

bioMerieux's revenue was reported to be €2.1 b in FY, 2016 which is a 7% increase from the previous period.

Revenue (FY, 2016)

€2.1 b

Revenue growth (FY, 2015 - FY, 2016), %

7%

Gross profit (FY, 2016)

€1.1 b

Gross profit margin (FY, 2016), %

52%

Net income (FY, 2016)

€179.2 m

EBIT (FY, 2016)

€282.5 m

Market capitalization (12-May-2017)

€7.4 b

Closing share price (12-May-2017)

€184.5

Cash (31-Dec-2016)

€178.6 m

EV

€7.6 b
bioMerieux's current market capitalization is €7.4 b.
FY, 2014FY, 2015FY, 2016

Revenue

€1.7 b€2 b€2.1 b

Revenue growth, %

16%7%

Cost of goods sold

€853.9 m€975.4 m€1 b

Gross profit

€844.5 m€989.2 m€1.1 b

Gross profit Margin, %

50%50%52%

Sales and marketing expense

€311.3 m€365.4 m€402.1 m

R&D expense

€205.8 m€238.9 m€271.9 m

General and administrative expense

€141.7 m€163.8 m€167.4 m

Operating expense total

€658.8 m€768.1 m€841.4 m

EBIT

€203.6 m€194.9 m€282.5 m

EBIT margin, %

12%10%13%

Interest expense

€7.2 m€24.6 m€17.6 m

Income tax expense

€51.7 m€65.9 m€79.8 m

Net Income

€135.5 m€110.3 m€179.2 m
FY, 2014FY, 2015FY, 2016

Cash

€119.7 m€147.1 m€178.6 m

Accounts Receivable

€449.3 m€445.1 m€465.8 m

Inventories

€299.2 m€355.8 m€404.4 m

Current Assets

€991.4 m€1.1 b€1.2 b

PP&E

€486.9 m€573.6 m€734.5 m

Goodwill

€437.8 m€459.3 m€470.6 m

Total Assets

€2.6 b€2.8 b€3 b

Accounts Payable

€188.9 m€176.9 m€175.6 m

Total Debt

€369.2 m€370.7 m€453.3 m

Current Liabilities

€611.5 m€683.5 m€759.8 m

Non-Current Liabilities

€556.2 m€582 m€647.6 m

Common Stock

€12 m€12 m€12 m

Additional Paid-in Capital

€1.2 b€1.4 b€1.4 b

Total Equity

€1.4 b€1.5 b€1.6 b

Debt to Equity Ratio

0.3 x0.2 x0.3 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x

Financial Leverage

1.9 x1.8 x1.9 x
FY, 2014FY, 2015FY, 2016

Net Income

€135.5 m€110.3 m€179.2 m

Cash From Operating Activities

€298.3 m€310 m€335.6 m

Purchases of PP&E

(€158.1 m)(€208.2 m)(€233 m)

Cash From Investing Activities

(€502.7 m)(€208 m)(€257.2 m)

Cash From Financing Activities

(€83.4 m)(€62.1 m)(€52.5 m)
Y, 2016

EV/EBIT

27 x

EV/CFO

22.7 x

Revenue/Employee

€224.3 k

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

1.9 x

bioMerieux Operating Metrics

FY, 2015FY, 2016

Patent Families

581529

Countries

150

Facilities

19

bioMerieux Market Value History

bioMerieux Online Presence

bioMerieux Company Life

You may also be interested in